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D ro t recogin alfa (or recombinant activated protein C) has re c e n t l y
been approved in most parts of the world for the treatment of
s e v e re sepsis associated with acute organ failure. Considering the
poor prognosis associated with severe sepsis and the dearth of
e ffective pharmacological interventions, such developments
should be embraced. However, critical review of this drug suggests
that enthusiasm for this new agent is pre m a t u re. 
Premature registration
D ro t recogin alfa has been re g i s t e red on the basis of one double-
blind placebo-controlled trial, the PROWESS study.1 This was a
phase 3 trial which enrolled 1 690 patients with systemic
inflammation and organ failure due to acute infection.  The
primary end-point was death from any cause at 28 days.  The
study concluded that 16 patients had to be treated to prevent 1
death (the mortality rate was 30.8% in the placebo group, and
24.7% in the dro t recogin group).  However, these results have been
questioned as evidenced by the controversial process to grant
marketing approval by the Food and Drug Administration (FDA).
The vote of the FDAAnti-Infective Drugs Advisory Committee
was split 10 to 10 as to whether activated protein C is safe and
e fficacious.  Indeed, four of the academic consultants who opposed
registration felt so strongly about the matter that they publicly
voiced their concerns in the scientific literature .2
The reasons for scepticism re g a rding registration of dro t re c o g i n
alfa are many. 
1. Not only did several changes occur during the trial
(amendment of the study protocol, introduction of a new placebo
and change in the manufacturing process of activated protein C),
but benefit of dro t recogin alfa over placebo could only be
demonstrated after protocol amendment.  Tw e n t y - e i g h t - d a y
survival was similar for both the placebo group and the
d ro t recogin group prior to such changes (30% v. 28%; 
p = 0.57).  Doubt remains as to whether protocol amendment could
in any way have affected the final outcomes of the study.2
2. Post hoc analysis of the PROWESS trial revealed that in less
s e v e rely ill patients there was a trend to excess mortality (15% v.
12%) and excess severe haemorrhage (4% v. 0%) in the dro t re c o g i n
g roup.  It was there f o re suggested that only patients with
A PACHE II scores of 25 or greater would be suitable candidates
for administration of this therapy.  However, the A PACHE II score
is a prognosticating system that was developed to pre d i c t
mortality of severely ill patients and its validity as a scre e n i n g
system to identify which patients should receive specific therapy is
unknown.  This is of particular importance in that it was applied in
an unconventional manner in the re s e a rch setting.  Whereas it is
usually based on the most aberrant values obtained within the first
24 hours of admission to the intensive care unit, in this case it was
based on the most aberrant clinical and laboratory values obtained
within the 24-hour period immediately preceding the
administration of study drug.  This means that in the trial the
A PACHE II score may not  always have incorporated the period of
resuscitation, i.e. patients with a relatively low A PACHE II score
may have been severely ill.2 This unconventional use of the
A PACHE II score also raises the question whether the tre a t m e n t
g roups were indeed well matched.  For example, despite similar
A PACHE II scores, more patients in the placebo group were
receiving vasopressors (75.5% v. 71.8%) or mechanical ventilation
(77.6% v. 73.3%) at time of randomisation.   
3. No relation between protein C levels before infusion or
m e a s u res of clotting after infusion and the efficacy of the dru g
could be demonstrated.  Hence, the proposed mechanisms of
action of dro t recogin are unpro v e n .2
Apart from the above, there are other concerns. 
Applicability of results in the ‘real world’
1. Considering the broad exclusion criteria in the trial setting
re g a rding bleeding risk, the true risk of severe haemorrhage with
this drug in a real-life setting is probably underestimated.  For
example, patients with aspirin use in the previous week, trauma,
t h rombocytopenia (< 30 · 1 09/l), chronic liver disease and chro n i c
renal failure were all excluded from entry into the study. Indeed, it
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has already been suggested that there may be a higher incidence of
intracranial haemorrhage with activated protein C in uncontro l l e d
than in controlled studies.3
2. From a South African perspective, there is a particular concern
that the majority of patients enrolled were from the developed
world.  South Africa as a developing nation contributed only 2.8%
of the entire study population.  This is relevant in that factors
influencing ICU admissions differ significantly along geographical
and socioeconomic lines.  For, example, HIV- and trauma-re l a t e d
ICU admissions are anticipated to be significantly more common
in Africa than in countries in North America and Europe.  Yet we
do not know the impact of dro t recogin alfa in HIV- i n f e c t e d
patients. The applicability of results to our local population is
t h e re f o re particularly questionable.
Inappropriate allocation of health care resources
1. As with many other innovative drugs, dro t recogin alfa is
expensive.  For a 70 kg patient, current treatment costs 
~R55 000.  This already reflects the recent 25% price re d u c t i o n
which has been possible for the local distributors as a result of
m o re than 25% strengthening of the rand/dollar exchange rate
since launch of this product into the South African market
(US$/ZAR as per Standard Bank of South Africa Limited).  To put
this expense into perspective, it would cost in the region of  R1
million to save one life assuming outcomes as per the PROWESS
trial.  This is in addition to the very high costs already incurred by
the treatment of sepsis.  Considering that 
6 - 10% of all ICU admissions in South Africa may be related to
sepsis (preliminary market re s e a rch — Eli Lilly), the potential
i n c remental costs for payers of health care are significant.    
2. Although the only trial to date claims a mortality benefit with
d ro t recogin over placebo, the diff e rence in numbers of patients
alive out of hospital at 1 month is 1%.  The question must there f o re
be posed whether deaths prevented are replaced by poor quality of
life and chronic morbid sequelae.4
3. Critical care in South Africa is suboptimal, with non-
intensivists commonly running ICUs.5 Instead of allocating health
c a re re s o u rces to an exorbitantly expensive drug with a dubious
risk/benefit ratio, appropriate training of intensivists and
a c c reditation of intensive care units (as suggested by Richard s5)
should be prioritised.  The Critical Care Society has identified
many basic intervention strategies (e.g. optimal ventilatory
support, tight glucose control) which, if applied corre c t l y, would
significantly improve the outcomes of critically ill patients in South
Africa, without increasing overall costs. Endeavours to elevate the
training of intensivists in South Africa should there f o re be
s u p p o r t e d .
C o n c l u s i o n s
For now, on the basis of both scientific and financial considerations
we believe that allocation of health care re s o u rces toward s
payment of dro t recogin alfa is unwise. 
F rom a scientific perspective, we concur with those members of
the FDAAnti-infectives Advisory Board who have called for
another trial that prospectively incorporates a prognostic scoring
system such as A PACHE II.  It is always questionable in a
h e t e rogeneous disease such as sepsis to grant marketing
authorisation on the basis of a single study.  This has already been
borne out by the case of HA-1Amonoclonal antibodies for severe
sepsis.  HA-1Amonoclonal antibodies were withdrawn as a re s u l t
of a second trial which not only showed that treatment was
i n e ffective, but that it was indeed dangerous in  a sub-group of
p a t i e n t s .6
F u r t h e r, even if the scientific benefits of this drug are eventually
confirmed, there still remains doubt as to whether the pro p o s e d
risk/benefit in a real-life situation would mirror that in a tightly
c o n t rolled clinical trial environment. This is of particular concern in
South Africa with its dearth of appropriately trained intensivists,
w h e re the general standard of critical care of medical diseases has
been questioned and where the demographic profile of patients is
p robably quite diff e rent from that of the developed world.
Obviously this concern could at that point be partially managed by
limiting use of dro t recogin to accredited well-trained intensivists.  
The dro t recogin case also highlights the need for diff e re n t i a l
d rug pricing for developing countries.  Such diff e rential pricing
applies not only to the public sector, but also to the private sector.
It is naïve to think that a country with a GDPone-tenth that of the
U S A7 has the ability to pay the same price for a drug as the
developed world.  The World Bank has suggested that health care
interventions may be considered cost-effective if they buy a year of
healthy life for less than the national per capita GDP.8 A l t h o u g h
we do not propose that this value should form the absolute
benchmark for health care interventions in the current South
African private health care sector, it is anticipated that it will be
c o n s i d e red by government’s proposed Pricing Committee (see
Medicines and Related Substances Control Amendment Bill). 
It is our opinion that if we are to achieve the goals of better
access to and equity in health care delivery, a wait-and-see
approach should be adopted regarding funding of drotrecogin
alfa in severely ill patients.  We call on all stakeholders to
support the principles that underpin the development of fair
allocation of health care resources.  This includes funders of
health care.   
We thank Mr Roger Wiseman for valuable research assistance. 
1. Bernard GR, Vincent JL, Laterre PF, et al.  Efficacy and safety of recombinant human activated
protein C for severe sepsis.  N Engl J Med 2001; 344: 699-709.
2. Warren HS, Suffredini AF, Eichacker PQ, Munford RS.  Risks and benefits of activated
protein C treatment for severe sepsis. N Engl J Med 2002; 347: 1027-1030.
3. Siegel JP. Assessing the use of activated protein C in the treatment of severe sepsis. N Engl J
Med 2002; 347: 1030-1034.
4. CBER. Biologics license application: recombinant human activated protein C (rhAPC)
[drotrecogin alfa (activated)] Xigris for severe sepsis.  Rockville, Md: Food and Drug
Administration, October 2001.
http://www.fda.gov/ohrms/dockets/ac/01/transcripts/3797t1.doc (accessed 28 April 2003)
5. Richards G. Critical care in South Africa. S Afr Med J 2002; 92: 883-884.
6. Anon. Prescire International 2003; 12: 55-57.
7. Anon. World Bank country data profiles.
http://www.worldbank.org/data/countrydata/countrydata.html (accessed 25 July 2001)
8. WHO.  Bulletin of the World Health Organisation.
http://www.who.int/bulletin/news/2000/vol.78no.2/cost-effectivevaccines.htm (accessed 27
August 2001).
501
July 2003, Vol. 93, No. 7  SAMJ
The value of innovation
William L Macias, Howard Levy
July 2003, Vol. 93, No. 7  SAMJ
SAMJ FORUM
Xigris (recombinant human activated protein c (rhAPC),
generic name  drotrecogin alfa (activated) (DrotAA) has been
approved for the treatment of patients with severe sepsis.
Approval by regulatory authorities around the world was
based on a single phase III study (PROWESS) with supporting
data from a single phase II study. At the time of the drug’s
approval, PROWESS was one of the largest studies of patients
with severe sepsis ever completed despite the study having
been stopped early because of overwhelming efficacy (as
determined by prospectively defined stopping rules agreed
upon with the United States Food and Drug Administration
(FDA)).  The final dataset for PROWESS contained an
estimated 160 000 000 data points and the final study report
comprised 7 338 pages.  The marketing authorisation
application contained an estimated 
26 000 pages.  Marketing authorisation for Xigris has been
granted in over 40 countries, and to date has not been denied
in any country in which the application has been completed.     
Taylor and Burns1 provide a review of DrotAAand question
whether its approval was premature.  However, their review
was based on limited data contained in an FDAadvisory
committee briefing document (189-page high-level summary of
the pre-clinical, clinical pharmacology and clinical
development history of DrotAA).  The issues they raise have
been discussed previously and have been reviewed in depth by
all regulatory agencies approving DrotAAfor the treatment of
patients with severe sepsis.  Taylor and Burns express the
concern that an amendment to the protocol substantially
modified the conduct of the study and somehow confounded
the results.  On this point, regulatory reviews have been
consistent in their conclusions that the amendment to the study
protocol did not alter the study outcome or diminish the
robustness of the findings.2 - 4
Taylor and Burns also raise questions about interpretation of
post hoc s u b g roup analyses.  However, the approval of Dro t A A
was based on results observed in the overall trial population
and not on the results within any particular subgroup.  For the
e n t i re PROWESS population, a p-value of 0.005 was achieved on
the prospectively defined primary endpoint of impro v e d
survival at 28 days.  The Dro t A At reatment benefit observed in
PROWESS is ‘ . . . one of the most powerful findings of
mortality benefit amongst drug development trials’.5 S u b g ro u p
analyses have been utilised by regulatory authorities only to
focus use of the drug in the population of patients thought to
have the most favourable benefit-risk profile.  In addition, the
unadjusted p-value of 0.005 observed in PROWESS was
unchanged after adjustment for A PACHE II score, age and
p rotein C levels.  There f o re, the concern expressed that potential
imbalances in baseline characteristics between treatment gro u p s
influenced the outcome of the study is not well founded.  
Taylor and Burns also comment that the applicability of the
PROWESS results may not be extrapolated to the ‘real world’
o r, specifically, to South Africa.  Importantly, the inclusion
criteria employed in the PROWESS trial were broader than
those of any previous phase III sepsis study (from which these
criteria were extracted), while the exclusion criteria were similar
to or less exclusive than other recent trials.6 , 7 F u r t h e r m o re ,
investigators in South Africa participated in the PROWESS trial,
and the administration of Dro t A A was associated with a 21%
reduction in the absolute risk of death and a 42% reduction in
the relative risk of death in their patients (data on file, Eli Lilly).
While subgroup data must always be interpreted with caution,
these results do not support the suggestion by Taylor and Burns
that the South African critical care system is not suff i c i e n t l y
sophisticated for patients to benefit from the use of DrotAA.  
F i n a l l y,  Taylor and Burns did not include in their re v i e w
long-term follow-up data on the PROWESS survivor
population, which demonstrated a reduction in in-hospital
mortality of 5.2% (p < 0.02), and that approximately two-third s
of the  survivors were discharged directly to their homes.8 D a t a
f rom the PROWESS trial indicate that the additional survivors
in the Dro t A At reatment arm are not saddled with ‘chro n i c
morbid sequelae’ and are as functional as placebo-tre a t e d
survivors.  They also did not include data from a phase IV
study of Dro t A A demonstrating highly comparable efficacy and
safety as seen in PROWESS and that the proportion of patients
experiencing a potential adverse drug reaction with
c o m m e rcially purchased Dro t A A is lower than that observed in
the phase III study.9 , 1 0
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agree entirely that health care resources should be distributed
wisely, based on sound medical judgement and appropriate
cost-effectiveness analyses.  However, we question the notion
that medical interventions in which ‘each individual patient
will be a direct beneficiary’ are in some way inherently
superior to those that produce ‘a statistically demonstrable
benefit for a patient population’.  From a societal view, adding
a year of life to an ‘identifiable’ individual is not inherently
better than: (i) adding one month of life to 12 individuals; 
(ii) providing a 10% chance of adding one year of life to each of
10 individuals; or (iii) supplying a 1% improvement in the
quality of life to 100 individuals for one year.  Such
comparisons are precisely the sort for which cost-effectiveness
analysis was designed.  
Cost-effectiveness is the ratio of the incremental cost of a
therapy to the incremental benefit (e.g. cost per life-year saved)
with or without adjustment for the quality of the incremental
benefit (e.g. cost per quality-adjusted life-year saved).  These
analyses allow assessment of the comparative beneficial impact
of expenditures on different health interventions and are based
on the premise that ‘for any given level of resources available,
society . . . wishes to maximize the total aggregate health
benefits conferred’.12 For the examples provided by Benatar and
Fleischer, cost-effectiveness ratios are widely disparate, with
chronic renal replacement having a cost-effectiveness ratio of
between $100 000 and $130 000 per quality-adjusted life-year
(in year 2000 US dollars) 13 and kidney transplantation having a
cost-effectiveness of up to $67 778 per quality-adjusted life-
year.14
Unfortunately, for many commonly adopted interventions
that require significant financial resources (particularly those
employed in the intensive care unit), data from randomised,
controlled trials are not available and, consequently, neither are
cost-effectiveness analyses.  This is not the case for DrotAA, for
which level 1 evidence supports use of the drug in patients
with severe sepsis15 and multiple cost-effectiveness analyses
indicate that its use compares favourably with other
interventions ($28 000 to $33 000 per life-year saved16 to $47 000
to $49 000 per quality-adjusted life-year saved17). Appropriate
use in the population of patients with the most favourable
benefit-risk profile will maximise the absolute benefit to
patients and improve the overall cost-effectiveness of the agent
(e.g. $27 400 per quality-adjusted life-year in patients with an
APACHE II score ³  2517).
We agree with Benatar and Fleischer that fairness,
transparency and accountability should be used when
determining how limited medical resources are to be invested.
In evaluating new and novel therapies, health care providers
and health care payers should analyse objectively and fairly all
available data, be transparent in their decision-making process,
and be accountable to patients and families for their
recommendations to accept or reject novel life-saving therapies.
This approach is the foundation of evidence-based medicine. 
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Oncology Symposium
Cape Town, 27 - 28 November 2003
A c o n f e rence on ‘Emerging Perspectives in Clinical Cancer Research’ will be held in Cape Town on 27 and 28 November 2003. 
It is being organised under the auspices of the Cancer Association of South Africa and the International Union against
Cancer (UICC). Participants include a number of experts from Europe and the USA, and topics will include many relevant
aspects of basic and clinical oncology. The full programme will be  circulated and publicised shortly and all those
interested in the many aspects of oncology should make a note of this special occasion. 
For further information, contact 
Ms Deborah Mcateer, deborah@curie.uct.ac.za or 
Professor B Bloch, bbloch@lando.co.za
